Human Study on MOG Antibodies and Multiple Sclerosis Features
In a study of adults with positive serum MOG antibodies, 23% were diagnosed with typical MS and 77% as equivocal. Over 1.9 years, 28% of typical MS patients relapsed, 55% developed new silent lesions, and half did not receive maintenance therapy. In contrast, 72% of equivocal patients started maintenance treatment, with 15% relapsing and 23% showing lesion resolution.
- Tags
- #MSResearch
- Most relevant to
- —
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- Limited
- Outcome
- Not reported
Why it matters
These findings highlight significant differences in disease management and outcomes between typical and equivocal MS cases, indicating diagnostic challenges and the need for tailored treatment approaches.
What this does not prove
The high proportion of equivocal cases indicates current diagnostic limitations and calls for ongoing clinical and radiologic reassessment to refine MS categorization.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-22
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Adults with clear positive serum MOG antibodies and MS features
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidenceClear Positive MOG Antibodies in Adults With Multiple Sclerosis Features: Diagnostic Challenges. ↗DOI: 10.1212/nxi.0000000000200662
Supporting passages (8)
publication datePublication date: 2026-10-22
follow upFor typical MS cases, half of the patients did not receive maintenance therapy after the first MOG-Ab-positive event, 28% relapsed, 55% developed new silent lesions, and none showed lesion resolution (median follow-up: 1.9 years).
findingsFor typical MS cases, half of the patients did not receive maintenance therapy after the first MOG-Ab-positive event, 28% relapsed, 55% developed new silent lesions, and none showed lesion resolution (median follow-up: 1.9 years).
limitationsThe substantial proportion of equivocal cases highlights current diagnostic limitations and underscores the need for longitudinal clinical and radiologic reassessment.
populationWe aimed to describe adults with clear positive serum MOG antibodies (MOG-Abs) presenting with MS features and rethink their nosological framework.
peer reviewedPublication types: Journal Article
subjectsMeSH terms: Humans; Female; Adult; Myelin-Oligodendrocyte Glycoprotein; Multiple Sclerosis; Male; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Retrospective Studies; Longitudinal Studies; Middle Aged; Autoantibodies; Diagnosis, Differential; Magnetic Resonance Imaging
study designMeSH terms: Humans; Female; Adult; Myelin-Oligodendrocyte Glycoprotein; Multiple Sclerosis; Male; Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; Retrospective Studies; Longitudinal Studies; Middle Aged; Autoantibodies; Diagnosis, Differential; Magnetic Resonance Imaging
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.